It targets the "reward" aspect of eating) the pleasure signals that drive overeating (rather than the hormonal hunger signals that GLP-1 medications address
In all models, the following fixed covariates were entered: assigned treatment (investigational product or placebo), baseline measurement of the outcome of interest, visit (day 14 1 day or day 28 1 day), visit in interaction with treatment, period (period 1 or period 2), sex and, for MIDT outcomes, incentive level
GLP-1 agonists preserve mitochondrial function in cardiomyocytes To assess the effects of GLP-1 agonists on mitochondrial function, we performed experiments on primary cardiomyocytes exposed to angiotensin II (Ang II) to mimic pathological stress conditions
For patients who arent candidates for surgery or prefer a non-invasive approach, GLP-1 therapy offers a powerful alternative
Glycemic improvements typically occur within 4-8 weeks, with measurable hemoglobin A1c reductions, while weight loss becomes noticeable within the first month and may continue progressively for up to 72 weeks based on clinical trials
Important Limitations of Use : [1] Not recommended as first-line therapy for patients inadequately controlled on diet and exercise